Top Indian drug makers issue several product recalls in U.S. market
Category: #headlines |   By Pankaj Singh |   Date: 2021-03-15

Top Indian drug makers issue several product recalls in U.S. market

India’s leading pharmaceutical firms, Dr. Reddy’s Laboratories, Jubilant Pharma, Sun Pharma (Sun Pharmaceutical Industries Ltd.), and Aurobindo Pharma have reportedly issued drug recalls in the United States, the world's largest market for pharmaceutical products, over a wide array of reasons.

According to the recent Enforcement Report from the USFDA (United States Food & Drug Administration), the Mumbai-based drug maker Sun Pharma has issued a recall for Cequa ophthalmic solution, which is primarily used for treating chronic dry eye disorder.

Sun Pharma’s U.S.-based subsidiary is recalling around 37,400 cartons (60 vials per carton) of ophthalmic solution owing to its ‘sub potent’ properties, said the U.S. health regulator.

Likewise, Dr. Reddy's Laboratories has recalled over 2,24,710 (500-count) and 10,440 (90-count) bottles of Atorvastatin Calcium tablets in the United States. The medication, which is used to avoid cardiovascular disease, is being recalled due to ‘failed impurities/degradation requirements,’ as claimed by the FDA.

Dr. Reddy’s U.S. unit issued a national recall in February 2021, which the USFDA classified as a Class III recall, meaning it was issued in a scenario in which an exposure to a violative product is unlikely to cause serious health consequences.

The Hyderabad-based drug-maker is also recalling 16,449 bottles of Progesterone Capsules (200 mg) in the U.S. market due to ‘failed dissolution requirements.’ For those unaware, Progesterone Capsules (200 mg) are used to cause menstrual cycles in women who have not yet reached menopause.

Meanwhile, Hyderabad’s Aurobindo Pharma is recalling 1,296 bottles of Famotidine tablets in the U.S. market due to the presence of foreign tablets, the FDA claims. Famotidine tablets are used to treat gastroesophageal reflux disease.

The USFDA noted that ibuprofen 400mg and famotidine 20mg tablets were found in famotidine 40mg. On January 20 this year, the company issued a national recall, which was treated as a Class II action by the USFDA.

Jubilant Cadista Pharmaceuticals is recalling 6,35,400 cartons of Methylprednisolone tablets, which are prescribed for immunosuppressive and anti-inflammatory effects, from the American market on the grounds of the illegible label.

Source Credit –

https://www.business-standard.com/article/companies/sun-pharma-dr-reddy-s-aurobindo-recall-products-in-the-us-market-121031400222_1.html

 

  • shareShare
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh     Twitter

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with Read more...

More News By Pankaj Singh

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

By Pankaj Singh

Airwaive and Shaurrya Teleservices (STS) has reportedly announced an international strategic collaboration to jointly build 5G wireless network service in India, assisting telecom providers in advancing 5G technology throughout the nation. Notably...

Valneva looking to capitalize on growing prevalence of Lyme disease

Valneva looking to capitalize on growing prevalence of Lyme disease

By Pankaj Singh

French drugmaker Valneva SE is now reportedly betting on its vaccine VLA15 for treating climate change-induced Lyme disease, as it looks to capitalize on growing prevalence of tick-borne illnesses following the disappointing sales of its COVID-19 vac...

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

By Pankaj Singh

Reliance Jio Infocomm Ltd., owned by billionaire industrialist Mukesh Ambani, was found to be the most aggressive participant in the government-backed 5G auction in India where several telecom behemoths agreed to invest at least USD 19 billion. Jio w...